HKG: 2575

Company Drug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Fineline Cube Oct 22, 2025

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod